Publisher： Bentham Science Publishers
E-ISSN： 1875-5704|2|4|369-381
ISSN： 1567-2018
Source： Current Drug Delivery, Vol.2, Iss.4, 2005-10, pp. : 369-381
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Selective targeting of ligand-targeted liposomes containing anticancer drugs or therapeutic genes to cell surface receptors expressed on cancer cells is a recognized strategy for improving the therapeutic effectiveness of conventional chemotherapeutics or gene therapeutics. Some recent advances in the field of ligand-targeted liposomes for the treatment of cancer are summarized including: selection criteria for the receptors to be targeted, choice of targeting ligands and choice of encapsulated therapeutics. Targeting of liposomes to solid tumors, versus angiogenic endothelial cells versus vascular targets is discussed. Ligand-targeted liposomes have shown considerable promise in preclinical xenograft models and are poised for clinical development.
Related content
Access to resources
Recommend
Ligand-Targeted Liposomal Therapies of Neuroblastoma
Current Medicinal Chemistry, Vol. 14, Iss. 29, 2007-12 ,pp. :
By Sawant Rupa R. Jhaveri Aditi M. Koshkaryev Alexander Qureshi Farooq Torchilin Vladimir P.
Journal of Drug Targeting, Vol. 21, Iss. 7, 2013-08 ,pp. :
Ligand-targeted receptor-mediated vectors for gene delivery
Expert Opinion on Therapeutic Patents, Vol. 8, Iss. 1, 1998-01 ,pp. :